The Patent Finder

Terms ending in 2041

Adimab, LLC

Every in-force patent on Adimab, LLC's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,679,892B7-H4 Antibodies and Methods of Use Thereof
In force
 · Medium confidence
Five Prime Therapeutics and Adimab, LLCIn forceMedium confidence
US 12,173,059LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
In force
 · Medium confidence
Scholar Rock, Inc.In forceMedium confidence
US 11,192,940Compounds Specific to Coronavirus S Protein and Uses Thereof
In force
 · High confidence
Invivyd, Inc.In forceHigh confidence
US 11,655,303Anti-CD39 Antibody Compositions and Methods
In force
 · Medium confidence
Surface Oncology, Inc.In forceMedium confidence
US 12,630,624ANTI-IL-27 Antibodies and Uses Thereof
In force
 · Low confidence
Surface Oncology, LLCIn forceLow confidence
5 of 5 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Adimab, LLC.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited